Dare Bioscience, Inc. SEC filings DARE
Dare Bioscience, Inc. has 777 filings in SEC EDGAR's recent list, going back to May 29, 2007. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 2, 2026 (listing notice). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 3, 2026 | — |
| D | Filing | Aug 20, 2026 | — |
| 253G2 | Filing | Aug 19, 2026 | — |
| 253G2 | Filing | Jul 17, 2026 | — |
| 253G2 | Filing | May 15, 2026 | — |
| QUALIF | Filing | Apr 1, 2026 | — |
| 1-A POS | Filing | Mar 30, 2026 | — |
| 253G2 | Filing | Mar 30, 2026 | — |
| 253G1 | Filing | Jan 7, 2026 | — |
| QUALIF | Filing | Jan 5, 2026 | — |
| 1-A/A | Filing | Dec 29, 2025 | — |
| 1-A | Filing | Nov 25, 2025 | — |
| EFFECT | Filing | Nov 26, 2024 | — |
| D | Filing | Nov 22, 2024 | — |
| CORRESP | Letter to the SEC | Nov 22, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 19, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 8, 2024 | — |
| CORRESP | Letter to the SEC | Sep 10, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 30, 2024 | — |
| EFFECT | Filing | May 10, 2024 | — |
| CORRESP | Letter to the SEC | May 8, 2024 | — |
| EFFECT | Filing | May 1, 2024 | — |
| CORRESP | Letter to the SEC | Apr 29, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 3, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 3, 2024 | — |
| D | Filing | Dec 26, 2023 | — |
| D/A | Filing | Sep 7, 2021 | — |
| EFFECT | Filing | Apr 7, 2021 | — |
| CORRESP | Letter to the SEC | Apr 5, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 2, 2021 | — |
| EFFECT | Filing | Jan 7, 2021 | — |
| CORRESP | Letter to the SEC | Jan 6, 2021 | — |
| CORRESP | Letter to the SEC | Jan 4, 2021 | — |
| CORRESP | Letter to the SEC | Jan 4, 2021 | — |
| EFFECT | Filing | Jun 8, 2020 | — |
| CORRESP | Letter to the SEC | Jun 4, 2020 | — |
| CORRESP | Letter to the SEC | May 29, 2020 | — |
| UPLOAD | Letter from the SEC | May 26, 2020 | — |
| EFFECT | Filing | May 12, 2020 | — |
| CORRESP | Letter to the SEC | May 8, 2020 | — |
| UPLOAD | Letter from the SEC | May 8, 2020 | — |
| SEC STAFF LETTER | Filing | Mar 5, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 10, 2020 | — |
| D | Filing | Dec 6, 2019 | — |
| CT ORDER | Filing | Apr 11, 2019 | — |
| EFFECT | Filing | Sep 21, 2018 | — |
| EFFECT | Filing | Sep 21, 2018 | — |
| CORRESP | Letter to the SEC | Sep 20, 2018 | — |
| CORRESP | Letter to the SEC | Sep 20, 2018 | — |
| CORRESP | Letter to the SEC | Sep 10, 2018 | — |
| UPLOAD | Letter from the SEC | Sep 7, 2018 | — |
| CT ORDER | Filing | Aug 30, 2018 | — |
| CT ORDER | Filing | May 8, 2018 | — |
| CT ORDER | Filing | Nov 28, 2017 | — |
| D | Filing | Jul 28, 2017 | — |
| DFAN14A | Filing | Jul 3, 2017 | — |
| UPLOAD | Letter from the SEC | Jun 19, 2017 | — |
| CORRESP | Letter to the SEC | Jun 19, 2017 | — |
| UPLOAD | Letter from the SEC | Jun 15, 2017 | — |
| CORRESP | Letter to the SEC | Jun 13, 2017 | — |
| PRER14A | Filing | Jun 13, 2017 | — |
| UPLOAD | Letter from the SEC | Jun 9, 2017 | — |
| CORRESP | Letter to the SEC | May 26, 2017 | — |
| PRER14A | Filing | May 26, 2017 | — |
| UPLOAD | Letter from the SEC | May 15, 2017 | — |
| CT ORDER | Filing | Jan 5, 2017 | — |
| CT ORDER | Filing | Dec 15, 2016 | — |
| D | Filing | Oct 17, 2016 | — |
| EFFECT | Filing | Oct 14, 2016 | — |
| CORRESP | Letter to the SEC | Oct 13, 2016 | — |
| CORRESP | Letter to the SEC | Oct 13, 2016 | — |
| UPLOAD | Letter from the SEC | Aug 16, 2016 | — |
| EFFECT | Filing | Aug 28, 2015 | — |
| CORRESP | Letter to the SEC | Aug 25, 2015 | — |
| UPLOAD | Letter from the SEC | Aug 19, 2015 | — |
| EFFECT | Filing | Apr 6, 2015 | — |
| CT ORDER | Filing | Apr 11, 2014 | — |
| EFFECT | Filing | Apr 10, 2014 | — |
| CORRESP | Letter to the SEC | Apr 7, 2014 | — |
| CORRESP | Letter to the SEC | Apr 7, 2014 | — |
| 8-A12B | Form 8-a | Apr 4, 2014 | — |
| CERTNAS | Auto-generated paper document | Mar 28, 2014 | — |
| UPLOAD | Letter from the SEC | Mar 25, 2014 | — |
| CORRESP | Letter to the SEC | Mar 21, 2014 | — |
| UPLOAD | Letter from the SEC | Mar 4, 2014 | — |
| DRS | Filing | Jan 30, 2014 | — |
| D | Filing | Dec 14, 2012 | — |
| D | Filing | Dec 15, 2011 | — |
| D | Filing | Nov 19, 2010 | — |
| D | Filing | Oct 13, 2010 | — |
| D | Filing | Jun 9, 2010 | — |
| D | Filing | Jul 27, 2009 | — |
| REGDEX | Auto-generated paper document | Jan 22, 2008 | — |
| REGDEX | Auto-generated paper document | May 29, 2007 | — |
Showing 94 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DARE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1401914
- Former names
- Cerulean Pharma Inc. (until Jul 5, 2017); Tempo Pharmaceuticals Inc (until Jan 22, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.